Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of DepoMed , a specialty pharmaceutical company focused on developing therapies to treat central nervous system disorders, popped by as much as 13% after announcing plans to acquire migraine medicine Cambia from Nautilus Neurosciences.
So what: Under the terms of the deal, DepoMed will pay Nautilus $48.7 million to acquire the U.S. rights to the drug and could be on the line for an addition $5 million based on whether annual net sales milestones are met. According to DepoMed's press release, Cambia is the only non-steroidal anti-inflammatory drug approved for the indication of treating migraines, with drug itself seeing revenue grow in excess of 30% last quarter.
Now what: It's not often that Wall Street rewards an acquisition, but the move by DepoMed to add a rapidly growing drug that'll be protected from generic competition for another 10 years to its product portfolio appears to make a lot of sense. The next step, obviously, is to see DepoMed make strides toward turning a profit in 2014. Until I see that black ink, though, I'd rather just be a casual observer from the sidelines.
Here's a stock you should be watching for 2014!
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article Why DepoMed Inc. Shares Popped originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong . Try any of our Foolish newsletter services free for 30 days . We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.